Supriya Lifescience opened lower at ₹866.90, compared with its previous close of ₹869.60. In the last trading session on 6 Nov 2026, the stock traded between ₹695.70 and ₹869.50, with an average traded price of ₹726.70. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Supriya Lifescience is now worth
₹ 17,800.00
giving a profit of
₹ 7,800.00 (78.00%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-173.90 (-20.00%)
Day High
₹869.50
Day Low
₹695.70
Day Open
₹866.90
Prev Close
₹869.60
Volume
19,61,177
Value Traded
₹142.52 Cr
1W Return
-19.97%
1M Return
-22.66%
3M Return
-23.85%
6M Return
0.72%
1Y Return
-12.63%
Market Cap (₹ Cr.)
5,599
PE Ratio
35.30
PB Ratio
5.84
Dividend Yield
0.11%
ROE
17.46%
ROCE
22.38%
Book Value (₹)
148.82
Face Value (₹)
2.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-19.97%
6 Weeks
-
1 Month
-22.66%
3 Months
-23.85%
9 Months
4.00%
No data available.
Supriya Lifescience Q2FY27 Results: Net profit falls 42% YoY to ₹29 crore
Net profit declined 42% YoY to ₹292.50 million in Q2FY27. Revenue grew 3% YoY to ₹2,062.97 million. EBITDA margin contracted by 14.31 percentage points to 22.04%. Europe's revenue share increased to 43% while LATAM dropped to 12%.
2 days agoSupriya Lifescience GM granted bail in NDPS Act case by Sessions Court
Sessions Court granted bail to Supriya Lifescience GM Sreekant Sreedharan on November 2, 2026. Proceedings relate to the Narcotic Drugs and Psychotropic Substances Act, 1985. Company states the order has no material impact on its operations. Update filed under Regulation 30 of SEBI LODR Regulations, 2015.
6 days agoSupreme Court stays coercive action against Supriya Lifescience directors
Supreme Court admitted judicial proceedings involving Supriya Lifescience. Interim stay granted on coercive action against directors and officers. Matter listed for hearing and currently sub judice. Company to update exchanges on material developments per SEBI norms.
20 days agoSupriya Lifescience files petition in Supreme Court over High Court order
Supriya Lifescience filed a petition in the Supreme Court on October 8, 2026. The filing challenges a High Court order disclosed earlier on September 23, 2026. The matter is sub judice, with no further comments expected from the company. Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015.
1mo agoSupriya Lifescience passes all resolutions at 18th AGM
All five ordinary resolutions passed with requisite majority at the 18th AGM. Final dividend of ₹1.00 per equity share declared for FY26. Dr. Saloni Wagh reappointed despite 4.13% dissent from public institutions. Meeting chaired by Joint MD Shivani Wagh due to Chairman's medical emergency.
1mo agoBombay HC allows provisional release of Supriya Lifescience's Ketamine consignment
Bombay High Court allowed provisional release of 200 kg Ketamine Hydrochloride consignment. Release conditioned on depositing ₹72 lakh with customs authorities within one week. Customs retains right to continue adjudication and criminal proceedings under NDPS Act.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,915.00 | +2.96% | ₹4,59,472.65 | 40.60 | +13.59% | |
| ₹11,097.00 | +7.52% | ₹2,94,590.48 | 93.50 | +61.21% | |
| ₹4,773.00 | +0.48% | ₹1,81,549.58 | 85.90 | +34.32% | |
| ₹2,370.00 | +1.28% | ₹1,28,054.00 | 94.70 | +141.89% | |
| ₹1,199.50 | +0.13% | ₹1,19,650.58 | 27.70 | +28.06% | |
| ₹1,370.00 | -0.22% | ₹1,14,351.20 | 41.50 | +13.67% | |
| ₹1,405.80 | -0.37% | ₹1,13,568.74 | 39.90 | -6.37% | |
| ₹2,582.90 | +1.69% | ₹1,06,685.42 | 46.30 | +11.86% | |
| ₹1,804.00 | +0.22% | ₹1,03,798.17 | 25.90 | +58.16% | |
| ₹1,997.00 | +0.45% | ₹91,320.81 | 17.40 | +2.12% | |
| ₹2,594.90 | +0.19% | ₹73,234.48 | 50.40 | +43.33% | |
| ₹5,304.00 | +0.13% | ₹63,417.28 | 28.60 | -6.02% |
An investment of ₹10,000 made 5 years ago in Supriya Lifescience is now worth
₹ 17,800.00
giving a profit of
₹ 7,800.00 (78.00%)
Note: Past profits do not guarantee future returns.